Marizomib: Additional Phase I data

Data from 36 patients with grade IV malignant glioma in an open-label, dose-escalation, North American Phase I trial showed that IV marizomib on days 1, 8 and 15

Read the full 289 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE